摘要
背景:目前,关节置换后感染的治疗方法为早期的一期清创手术和标准的二期翻修手术,单纯使用抗生素治疗疗效甚微,课题组拟使用载药缓释微球来探索局部抑制感染治疗方法的可行性。目的:观察人β-防御素3/聚乳酸-羟基乙酸缓释微球的理化性质及体外释药特性。方法:采用改良复乳-溶剂挥发法,以聚乳酸-羟基乙酸为载体材料,人β-防御素3为药物制备人β-防御素3/聚乳酸-羟基乙酸缓释微球。采用扫描电镜观察其表面形态,标尺精确测量每个微球大小,采用分光光度计测定微球的载药量和包封率,通过测定人β-防御素3/聚乳酸-羟基乙酸微球的缓释时间,分析微球的体外释药特性。结果与结论:(1)人β-防御素3/聚乳酸-羟基乙酸缓释微球的表面光滑,均匀分布,流动性良好,其平均粒径为219.49 nm;(2)人β-防御素3的载药量为(20.67±0.17)%,包封率为(54.52±1.31)%;(3)人β-防御素3的25 d累计释药量平均为(74.12±0.43)%;(4)结果表明,人β-防御素3/聚乳酸-羟基乙酸缓释微球的体外释药性能良好,理论上可以达到缓释抗菌的目的,为后续的动物抗菌实验研究奠定基础。
BACKGROUND： A simple use of antibiotic drugs as anti-infection therapy after joint replacement is not enough for subsequent debridement and secondary revision surgeries. Therefore, our team intended to confirm the feasible use of controlled-release microspheres in the local anti-infection treatment.OBJECTIVE： To prepare the Human beta defense 3 （HBD-3）/poly（lactic-co-glycolic acid） （PLGA） micro-spheres and to investigate the microsphere physicochemical properties and drug release profile in vitro.METHODS： With PLGA as a carrier,HBD-3/PLGA controlled-release microspheres were prepared by using double emulsion-solvent evaporation method. Scanning electron microscopy was used to observe its surface morphology.The size of each microsphere was accurately determined using scaleplate. Drug loading capacity and encapsulation efficiency of HBD-3/PLGA controlled-release microspheres were calculated using spectrophotometer. HBD-3/PLGA microsphere controlled-release time was determined in order to analyze the drug release profile of the microsphere. RESULTS AND CONCLUSION： The HBD-3/PLGA controlled-release microsphere possessed smooth surface, uniform distribution and good liquidity.The average particle size was 219.49 nm, the drug loading capacity of HBD-3 was （20.67±0.17）% and the encapsulation efficiency was （54.52±1.31）%. The cumulative release percentage of HBD-3 was（74.12±0.43）%. The HBD-3/PLGA controlled-release microsphere has well controlled-release performance in vitro. In theory, the purpose of antibacterial controlled-release can be achieved,laying a foundation for subsequent animal antibacterial experiments.
出处
《中国组织工程研究》
CAS
北大核心
2017年第10期1514-1519,共6页
Chinese Journal of Tissue Engineering Research
基金
上海市卫生局课题(2012353)
课题名称:β-防御素-3/聚乳酸聚乙醇酸缓释微球抑制人工关节术后生物膜形成的机制研究~~
